8-K: Sana Biotech Reports Q4/FY25, Boosts ATM to $150M

Sana Biotechnology announced its fourth quarter and full year 2025 financial results, highlighted positive clinical progress in type 1 diabetes and blood cancers, and amended its at-the-market offering program to raise up to $150 million.

Summary

• Sana Biotechnology reported a GAAP net loss of $58.8 million ($0.21 per share) for Q4 2025 and $244.2 million ($0.96 per share) for the full year 2025.
• Cash, cash equivalents, and marketable securities stood at $138.4 million as of December 31, 2025, compared to $152.5 million at December 31, 2024.
• The company expects its cash runway to extend into late 2026.
• Positive 12-month clinical results were shared from the UP421 type 1 diabetes study, demonstrating safety, immune evasion, and function of hypoimmune-modified pancreatic islet cells transplanted without immunosuppression.
• The New England Journal of Medicine published positive 12-week clinical results from the UP421 type 1 diabetes study.
• Significant progress was made on SC451, a hypoimmune-modified, stem cell-derived therapy for type 1 diabetes, with an Investigational New Drug (IND) application expected to be filed and a Phase 1 trial to begin as early as this year.
• Preclinical data for SG293, a next-generation in vivo CAR T product candidate for blood cancers, showed deep B-cell depletion and immune reset in non-human primates, with first-in-human data expected as early as this year.
• An amended and restated sales agreement with TD Securities (USA) LLC allows the company to sell up to $150.0 million of common stock through an at-the-market (ATM) offering program.
• In 2025, Sana raised aggregate gross proceeds of $133.7 million from ATM sales ($47.4 million) and an equity financing ($86.3 million).
• Brian Piper was appointed as Executive Vice President, Chief Financial Officer in Q1 2026.
• The company recorded a non-cash impairment of long-lived assets of $44.6 million for the twelve months ended December 31, 2025, primarily related to its manufacturing facility and office space, as it plans to use third-party contract development and manufacturing organizations (CDMOs).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive update. While financial losses and asset impairment are notable, the significant clinical progress in two key platforms (hypoimmune and fusogen) and the extension of the cash runway provide strong positive momentum for future value creation.

Positives

• Positive 12-month clinical results for UP421 in type 1 diabetes, demonstrating safety, immune evasion, and function of transplanted hypoimmune-modified pancreatic islet cells without immunosuppression.
• Publication of UP421's 12-week clinical results in the prestigious New England Journal of Medicine, lending significant scientific credibility to the hypoimmune platform.
• Advancement of SC451, a more scalable stem cell-derived therapy for type 1 diabetes, with an IND filing and Phase 1 trial expected as early as this year.
• Promising preclinical data for SG293, a next-generation in vivo CAR T candidate for blood cancers, demonstrating deep B-cell depletion and immune reset in non-human primates without the use of lymphodepleting chemotherapy.
• Expectation to generate first-in-human data for SG293 as early as this year.
• Preclinical data published in Nature Biotechnology demonstrating potent in vivo gene editing of hematopoietic stem cells using fusogen technology, broadening the platform's application.
• Expected cash runway into late 2026, providing financial flexibility for ongoing development programs.
• Successful capital raises in 2025, totaling $133.7 million in gross proceeds from ATM sales and a public offering.
• Full year 2025 GAAP net loss decreased to $244.2 million from $266.8 million in 2024, and non-GAAP operating cash burn decreased to $138.5 million from $195.1 million in 2024.

Negatives

• The GAAP net loss for Q4 2025 increased to $58.8 million, compared to $49.1 million for Q4 2024.
• A significant non-cash impairment of long-lived assets totaling $44.6 million was recorded for the full year 2025, primarily related to the write-down of internal manufacturing capabilities and office space.
• Non-cash expenses related to research and development success payments and contingent consideration increased significantly to $29.4 million for FY 2025, compared to a non-cash gain of $8.9 million in FY 2024.
• Continued high research and development expenses ($132.0 million for FY 2025) and general and administrative expenses ($44.3 million for FY 2025), reflecting ongoing operational costs for a development-stage company.
• Reliance on at-the-market (ATM) offerings for capital, which can lead to share dilution for existing shareholders.

Risks

• Inherent risks in drug development, including uncertainties associated with the initiation, cost, timing, progress, and results of current and future research and development programs, preclinical and clinical trials.
• Potential for economic, market, and social disruptions to impact operations and financial performance.
• Forward-looking statements are subject to significant uncertainties and may not materialize as predicted.
• There is no assurance that TD Cowen will be successful in selling Placement Shares under the ATM agreement, impacting the company's ability to raise capital.
• The company may cease to be eligible to use an automatic shelf registration statement, which could complicate future capital raises.
• The company's ability to maintain compliance with Nasdaq listing rules is crucial for its public trading status.

Future Outlook

Sana Biotechnology expects to file an Investigational New Drug (IND) application for SC451 in type 1 diabetes and commence a Phase 1 clinical trial as early as this year. The company also anticipates generating first-in-human data for its next-generation in vivo CAR T product candidate, SG293, in blood cancers as early as this year. The company projects its current cash position will provide a runway into late 2026.

Management Comments

• "Meaningful scientific and operational progress in 2025 has positioned us well to generate human proof-of-concept data over the next 12-18 months for SC451 in type 1 diabetes and SG293 in blood cancers." Steve Harr, President and Chief Executive Officer.
• "Clinical data for UP421, a study which is now out beyond a year, provide the first known example of transplanting an allogeneic cell therapy for the treatment of type 1 diabetes without any immunosuppression." Steve Harr.
• "These results, when combined with progress in the field of transplanting pancreatic islets, make us optimistic that SC451, which incorporates the same hypoimmune gene edits into a more scalable manufacturing platform, can lead to a functional cure for people with type 1 diabetes, meaning normal blood glucose, no more insulin injections, and no immunosuppression." Steve Harr.
• "Moving to the fusogen platform, we made improvements to our in vivo CAR T platform with our next-generation SG293 candidate, offering the potential for a simple, one-time, off-the-shelf treatment without the use of conditioning chemotherapy for the treatment of B cell cancers and B cell-mediated autoimmune diseases." Steve Harr.
• "We look forward to beginning clinical trials for both of these therapies this year. With two powerful platforms advancing in parallel, we look to drive meaningful clinical benefit for patients." Steve Harr.

Industry Context

StockSavvy.ai notes that Sana Biotechnology operates at the forefront of cell and gene therapy, a rapidly evolving sector with high potential for transformative medicines. The positive 12-month clinical data for UP421 in type 1 diabetes, particularly the demonstration of immune evasion without immunosuppression, represents a significant advancement in allogeneic cell therapy for autoimmune diseases. This could position Sana as a leader in developing "off-the-shelf" cell therapies. Similarly, the progress with SG293 in in vivo CAR T cells addresses a key challenge in oncology and autoimmune treatment by aiming for a non-chemotherapy, one-time treatment, potentially differentiating it from existing CAR T therapies that require complex ex vivo manufacturing and lymphodepletion. The shift to CDMOs for manufacturing reflects a broader industry trend where specialized contract organizations offer cost efficiencies and scalability, especially for companies with diverse and evolving pipeline needs.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct benchmarking.
• The 12-month clinical results for UP421, demonstrating immune evasion of allogeneic islet cells without immunosuppression, are highly significant. This is a major hurdle in allogeneic transplantation, and if replicated and scaled with SC451, it would represent a breakthrough compared to current islet transplantation methods (e.g., Edmonton Protocol) that typically require lifelong immunosuppression.
• For in vivo CAR T, SG293's preclinical data showing deep B-cell depletion without lymphodepleting chemotherapy in non-human primates is a notable advancement. Current approved CAR T therapies (e.g., Kymriah, Yescarta) all require lymphodepleting chemotherapy, which carries significant toxicity. If SG293 can achieve similar efficacy in humans without this requirement, it would set a new standard for patient convenience and safety in CAR T therapy.
• The impairment of long-lived assets and the strategic move to utilize CDMOs align with a trend seen in many biotech companies, especially those in early to mid-stage development, to optimize capital allocation and leverage external expertise rather than building costly internal manufacturing infrastructure prematurely.

Management Changes

Related Party Transactions

• Success payments to Cobalt Biomedicine, Inc. and the President and Fellows of Harvard College, which are recorded at fair value and remeasured each reporting period.
• Contingent consideration to Cobalt Biomedicine, Inc. upon achievement of certain milestones, also recorded at fair value and remeasured each reporting period.

Stakeholder Impact

• Shareholders: Potential for dilution from the new ATM offering, but also potential for significant long-term value creation if pipeline candidates (SC451, SG293) achieve clinical success. The appointment of a new CFO may instill confidence in financial management.
• Employees: Portfolio prioritization in Q4 2024 led to lower personnel-related costs, indicating potential headcount adjustments. The new CFO appointment impacts leadership.
• Patients: Positive clinical updates for UP421 and progress on SC451 and SG293 offer hope for future transformative therapies for type 1 diabetes, B-cell cancers, and B-cell mediated autoimmune diseases.
• Creditors/Investors: The extended cash runway into late 2026 provides financial stability, while the ATM offering provides a mechanism for future capital.

Next Steps

• File Investigational New Drug (IND) application for SC451 in type 1 diabetes as early as this year.
• Begin Phase 1 clinical trial for SC451 as early as this year.
• Generate first-in-human data for SG293 in blood cancers as early as this year.
• Continue development of SC451 and SG293.
• Utilize CDMOs to meet manufacturing needs.

Key Dates

Recommendation

Sana Biotechnology presents a mixed financial picture with increased Q4 net loss and significant asset impairment, but this is balanced by compelling positive clinical and preclinical data for its lead programs in type 1 diabetes and B-cell cancers. The successful demonstration of immune evasion without immunosuppression for UP421 is a significant scientific validation, and the planned IND and first-in-human data for SC451 and SG293 this year represent critical near-term catalysts. The extended cash runway provides operational flexibility. However, the company remains in early-stage clinical development, and the path to market is long, costly, and uncertain. The reliance on ATM offerings for capital also introduces potential dilution. A "hold" recommendation reflects the high-risk, high-reward nature of early-stage biotech, acknowledging both the promising scientific advancements and the ongoing financial challenges and execution risks.

Keywords

Biotechnology, Cell therapy, Gene therapy, Type 1 diabetes, CAR T, Oncology, Autoimmune diseases, Hypoimmune platform, Fusogen technology, SEC filing, Financial results, Clinical trials, IND filing, ATM offering, Capital raise, NASDAQ